Introduction: Complex perianal fistulas represent one of the most debilitating manifestations of Crohn’s disease, often causing chronic pain, drainage, recurrent infections, and substantial impairment in quality of life. Despite advances in biologic therapy, fistula healing remains difficult to achieve and sustain.
Introduction:
Complex perianal fistulas represent one of the most debilitating manifestations of Crohn’s disease, often causing chronic pain, drainage, recurrent infections, and substantial impairment in quality of life. Despite advances in biologic therapy, fistula healing remains difficult to achieve and sustain. Darvadstrocel, an allogeneic adipose-derived mesenchymal stem cell therapy, generated considerable enthusiasm following the positive ADMIRE-CD trial, which demonstrated improved fistula healing in selected patients with refractory disease.
Problem Statement:
Although earlier studies supported the efficacy of darvadstrocel, its performance in a broader international population and contemporary treatment setting remained uncertain. Confirmation of benefit in a larger phase 3 trial was necessary before establishing its role in routine management of complex perianal Crohn’s disease.
Summary:
The ADMIRE CD II trial evaluated the efficacy and safety of darvadstrocel in patients with complex perianal Crohn’s disease across Europe, Israel, and North America. All participants underwent standardized surgical preparation, including fistula curettage and closure of the internal opening, before receiving either darvadstrocel or placebo. Contrary to expectations generated by the earlier ADMIRE-CD study, darvadstrocel did not demonstrate superiority over placebo for the primary endpoint of combined remission at 24 weeks. Clinical remission rates and time to remission were also comparable between the treatment groups, indicating no meaningful therapeutic advantage. Importantly, the study confirmed a favorable safety profile, with adverse events occurring at similar rates in both groups and no new safety concerns identified. These findings represent a significant setback for stem cell-based therapy in complex perianal Crohn’s disease and highlight the challenges of translating promising early results into consistent benefits across broader patient populations. While darvadstrocel remains biologically attractive and well tolerated, the negative results of ADMIRE CD II raise important questions regarding patient selection, treatment timing, fistula characteristics, and trial design. Future research will be needed to identify subgroups most likely to benefit and to refine regenerative approaches for fistula healing in Crohn’s disease.
Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...
Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...
Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...
Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...
Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.